4
Changes in Ownership
Tyra Biosciences, Inc. Filed Acc 0001209191-23-021947
Chief Executive Officer sold 4,327 shares at an average $16.07 ($69,556)
- Chief Executive Officer acquired 4,327 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Harris Todd Chief Executive Officer | 2023-03-29 | Option exercise | +1,420 | $2.25 | $3,195 | 1,702,696 | D: show line 1 in the form |
| Harris Todd Chief Executive Officer | 2023-03-29 | Sale | −1,420 | $16.18 | $22,981 | 1,701,276 | D: show line 2 in the form |
| Harris Todd Chief Executive Officer | 2023-03-30 | Option exercise | +2,407 | $2.25 | $5,416 | 1,703,683 | D: show line 3 in the form |
| Harris Todd Chief Executive Officer | 2023-03-30 | Sale | −2,407 | $16.02 | $38,552 | 1,701,276 | D: show line 4 in the form |
| Harris Todd Chief Executive Officer | 2023-03-31 | Option exercise | +500 | $2.25 | $1,125 | 1,701,776 | D: show line 5 in the form |
| Harris Todd Chief Executive Officer | 2023-03-31 | Sale | −500 | $16.05 | $8,023 | 1,701,276 | D: show line 6 in the form |
| Open-market sales · 4,327 sh · avg $16.07 · $69,556 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Harris Todd Chief Executive Officer | 2023-03-29 | Option exercise · Stock Option (Right to Buy) | −1,420 | 402,444 | D: show line 7 in the form | |||||
| Harris Todd Chief Executive Officer | 2023-03-30 | Option exercise · Stock Option (Right to Buy) | −2,407 | 400,037 | D: show line 8 in the form | |||||
| Harris Todd Chief Executive Officer | 2023-03-31 | Option exercise · Stock Option (Right to Buy) | −500 | 399,537 | D: show line 9 in the form |
Loading xslF345X04/doc4.xml…